Evercore ISI lowered the firm’s price target on AbbVie (ABBV) to $235 from $236 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
- AbbVie Quietly Expands Its Obesity Bet With New ABBV-295 Trial
- AbbVie’s ABBV-951 Parkinson’s Extension Study Completes, Setting Up Key Long-Term Safety Readout
- AbbVie price target raised to $298 from $294 at Piper Sandler
- AbbVie Shareholders Back Directors, Maintain Governance Structure